Medicure Inc (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, on Monday announced its financial results for the quarter ended 31 March 2019.
The company reported net revenue from the sale of AGGRASTAT (tirofiban hydrochloride) at USD4.8m in the quarter ended 31 March 2019, compared to USD6.1m for the same period in 2018.
Net loss for the quarter ended 31 March 2019 was USD2.8m, compared to net income of USD1.4m for the year-ago period.
As of 31 March 2019, the company had unrestricted cash and short-term investments totalling USD55.5 million compared to USD71.9 million as of 31 December 2018. The decrease in cash is primarily due to the investment made in Sensible Medical Innovations Ltd. and a decrease in the value of the US dollar as of 31 March 2019 compared to 31 December 2018.
Acerus and Aytu Bioscience to Co-promote Natesto in the United States
Amgen reports financial results for Q2 2019
Pfizer to integrate Upjohn with Mylan to establish new global pharmaceutical company
Neurocrine Biosciences reports half-year ended 30 June 2019 financial results
Thermo Fisher Scientific reports financial results for Q2 2019
Veloxis Pharmaceuticals revises 2019 outlook
NANOBIOTIX collects revenues of EUR31.9,000 for Q2 2019
Seattle Genetics incurs net loss of USD79.2m in Q2 2019
Baxter's board announces USD0.22 per share dividend pay order
Johnson & Johnson declares dividend of USD0.95 per share for Q3 2019
Sun Pharma Launches Ezallor Sprinkle in the US for People Who Have Difficulty Swallowing
PanTheryx Aims to End Diarrheal Disease in Cambodia
CCA Industries Inc swings to income of USD349,320 for Q2 2019
Oncimmune Holdings signs commercial collaboration with R-Pharm JSC